Last reviewed · How we verify

NCT06176443

Impact of an Increased Restrictive Factor of One Anastomosis Gastric Bypass on Metabolic Outcomes Type 2 Diabetes.

Completed NA Last updated 21 November 2024
What this trial tests

NA trial testing One anastomosis gastric bypass with combined fundoplication in Obesity, Morbid in 300 participants. Completed in 1 May 2024.

Timeline
13 January 2020
Primary endpoint
13 January 2024
1 May 2024

Quick facts

Lead sponsorThe Society of Bariatric and Metabolic Surgeons of Kazakhstan
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment300
Start date13 January 2020
Primary completion13 January 2024
Estimated completion1 May 2024
Sites1 location across Kazakhstan

Drugs / interventions tested

Conditions studied

Sponsor

The Society of Bariatric and Metabolic Surgeons of Kazakhstan

Who can join

Adults 18 to 60, any sex, with Obesity, Morbid or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the effect of an increased restrictive factor of one gastric anastomosis (OAGB) using a "FundoRing" fundoplication on metabolic outcomes in type 2 diabetes mellitus. The randomized controlled trial compared two interventional procedures: one group - using the original fundoplication procedure to enhance the restrictive effect and another group without fundoplication in the standard version of the OAGB.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity, Morbid

Currently open trials in the same condition.

Other The Society of Bariatric and Metabolic Surgeons of Kazakhstan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06176443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing